Glenmede Trust’s Merck MRK Stock Holding History

Glenmede Trust’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-68	Closed	-$23K	–	1237
2020 Q4	$23K	Buy	+68	New	+$5.2K	﹤0.01%	1149

Other funds holding MRK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Glenmede Trust's MRK Position: Q1 2026 in Review

Glenmede Trust reduced its Merck (MRK) stake by 0.57% in Q1 2026, selling an estimated $346K and leaving 521,378 shares worth $62.7M. The position accounts for 0.31% of the portfolio, ranked #70.

Glenmede Trust first reported a position in MRK in Q2 2013 and has held it in 50 quarters since. The position peaked at $237M in Q2 2017. 3,777 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

Glenmede Trust held 521,378 shares of Merck worth $62.7M as of Q1 2026.
Glenmede Trust sold 2,993 Merck shares in Q1 2026, an estimated $346K.
Merck made up 0.31% of Glenmede Trust's portfolio in Q1 2026, its #70 holding.
Glenmede Trust first reported a position in Merck in Q2 2013 and has held it in 50 quarters since.
Glenmede Trust's Merck position peaked at $237M in Q2 2017.
3,777 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.